220 related articles for article (PubMed ID: 27777881)
1. Tumor infiltrating lymphocytes in triple negative breast cancer receiving neoadjuvant chemotherapy.
Castaneda CA; Mittendorf E; Casavilca S; Wu Y; Castillo M; Arboleda P; Nunez T; Guerra H; Barrionuevo C; Dolores-Cerna K; Belmar-Lopez C; Abugattas J; Calderon G; De La Cruz M; Cotrina M; Dunstan J; Gomez HL; Vidaurre T
World J Clin Oncol; 2016 Oct; 7(5):387-394. PubMed ID: 27777881
[TBL] [Abstract][Full Text] [Related]
2. Prognostic significance of tumor-infiltrating CD8+ and FOXP3+ lymphocytes in residual tumors and alterations in these parameters after neoadjuvant chemotherapy in triple-negative breast cancer: a retrospective multicenter study.
Miyashita M; Sasano H; Tamaki K; Hirakawa H; Takahashi Y; Nakagawa S; Watanabe G; Tada H; Suzuki A; Ohuchi N; Ishida T
Breast Cancer Res; 2015 Sep; 17(1):124. PubMed ID: 26341640
[TBL] [Abstract][Full Text] [Related]
3. Interaction between Molecular Subtypes and Stromal Immune Infiltration before and after Treatment in Breast Cancer Patients Treated with Neoadjuvant Chemotherapy.
Hamy AS; Bonsang-Kitzis H; De Croze D; Laas E; Darrigues L; Topciu L; Menet E; Vincent-Salomon A; Lerebours F; Pierga JY; Brain E; Feron JG; Benchimol G; Lam GT; Laé M; Reyal F
Clin Cancer Res; 2019 Nov; 25(22):6731-6741. PubMed ID: 31515462
[TBL] [Abstract][Full Text] [Related]
4. Association of tumor-infiltrating lymphocytes before and after neoadjuvant chemotherapy with pathological complete response and prognosis in patients with breast cancer.
Hong J; Rui W; Fei X; Chen X; Shen K
Cancer Med; 2021 Nov; 10(22):7921-7933. PubMed ID: 34562054
[TBL] [Abstract][Full Text] [Related]
5. Significance of Tumor-Infiltrating Lymphocytes and the Expression of Topoisomerase IIα in the Prediction of the Clinical Outcome of Patients with Triple-Negative Breast Cancer after Taxane-Anthracycline-Based Neoadjuvant Chemotherapy.
Rao N; Qiu J; Wu J; Zeng H; Su F; Qiu K; Wu J; Yao H
Chemotherapy; 2017; 62(4):246-255. PubMed ID: 28472798
[TBL] [Abstract][Full Text] [Related]
6. Immunotyping of tumor-infiltrating lymphocytes in triple-negative breast cancer and genetic characterization.
Gomez-Macias GS; Molinar-Flores G; Lopez-Garcia CA; Santuario-Facio S; Decanini-Arcaute H; Valero-Elizondo J; Treviño-Alvarado V; Ortiz-Lopez R; Dono A; Esteban-Zubero E; Alatorre-Jimenez MA; Garza CV; Peña-Curiel O; Cardona-Huerta S
Oncol Lett; 2020 Nov; 20(5):140. PubMed ID: 32934708
[TBL] [Abstract][Full Text] [Related]
7. Prognostic value of tumor-infiltrating lymphocytes in patients with triple-negative breast cancer: a systematic review and meta-analysis.
Gao G; Wang Z; Qu X; Zhang Z
BMC Cancer; 2020 Mar; 20(1):179. PubMed ID: 32131780
[TBL] [Abstract][Full Text] [Related]
8. Predictive and prognostic impact of tumour-infiltrating lymphocytes in triple-negative breast cancer treated with neoadjuvant chemotherapy.
Herrero-Vicent C; Guerrero A; Gavilá J; Gozalbo F; Hernández A; Sandiego S; Algarra MA; Calatrava A; Guillem-Porta V; Ruiz-Simón A
Ecancermedicalscience; 2017; 11():759. PubMed ID: 28900472
[TBL] [Abstract][Full Text] [Related]
9. A nomogram to predict pathologic complete response (pCR) and the value of tumor-infiltrating lymphocytes (TILs) for prediction of response to neoadjuvant chemotherapy (NAC) in breast cancer patients.
Hwang HW; Jung H; Hyeon J; Park YH; Ahn JS; Im YH; Nam SJ; Kim SW; Lee JE; Yu JH; Lee SK; Choi M; Cho SY; Cho EY
Breast Cancer Res Treat; 2019 Jan; 173(2):255-266. PubMed ID: 30324273
[TBL] [Abstract][Full Text] [Related]
10. Changes in Tumor-infiltrating Lymphocytes After Neoadjuvant Chemotherapy and Clinical Significance in Triple Negative Breast Cancer.
Lee H; Lee M; Seo JH; Gong G; Lee HJ
Anticancer Res; 2020 Apr; 40(4):1883-1890. PubMed ID: 32234876
[TBL] [Abstract][Full Text] [Related]
11. Prognostic relevance of tumor‑infiltrating lymphocytes in residual tumor tissue from patients with triple‑negative breast cancer following neoadjuvant chemotherapy: A systematic review and meta‑analysis.
Cao B; Zhang Z; Wang C; Lv X
Oncol Lett; 2023 Oct; 26(4):441. PubMed ID: 37664648
[TBL] [Abstract][Full Text] [Related]
12. Prediction of Treatment Response to Neoadjuvant Chemotherapy in Breast Cancer by Subtype Using Tumor-infiltrating Lymphocytes.
Asano Y; Kashiwagi S; Goto W; Takada K; Takahashi K; Hatano T; Takashima T; Tomita S; Motomura H; Ohsawa M; Hirakawa K; Ohira M
Anticancer Res; 2018 Apr; 38(4):2311-2321. PubMed ID: 29599354
[TBL] [Abstract][Full Text] [Related]
13. Tumor-infiltrating lymphocytes are correlated with response to neoadjuvant chemotherapy in triple-negative breast cancer.
Ono M; Tsuda H; Shimizu C; Yamamoto S; Shibata T; Yamamoto H; Hirata T; Yonemori K; Ando M; Tamura K; Katsumata N; Kinoshita T; Takiguchi Y; Tanzawa H; Fujiwara Y
Breast Cancer Res Treat; 2012 Apr; 132(3):793-805. PubMed ID: 21562709
[TBL] [Abstract][Full Text] [Related]
14. Prognostic Impact of Stromal Immune Infiltration before and after Neoadjuvant Chemotherapy (NAC) in Triple Negative Inflammatory Breast Cancers (TNIBC) Treated with Dose-Dense Dose-Intense NAC.
Campedel L; Blanc-Durand P; Bin Asker A; Lehmann-Che J; Cuvier C; De Bazelaire C; Teixeira L; Becourt S; Ledoux F; Hocini H; Bourstyn E; Miquel C; Guillerm S; Charveriat P; Espié M; De Roquancourt A; Hamy AS; Giacchetti S
Cancers (Basel); 2020 Sep; 12(9):. PubMed ID: 32957722
[TBL] [Abstract][Full Text] [Related]
15. Predictive Value of Tertiary Lymphoid Structures Assessed by High Endothelial Venule Counts in the Neoadjuvant Setting of Triple-Negative Breast Cancer.
Song IH; Heo SH; Bang WS; Park HS; Park IA; Kim YA; Park SY; Roh J; Gong G; Lee HJ
Cancer Res Treat; 2017 Apr; 49(2):399-407. PubMed ID: 27488875
[TBL] [Abstract][Full Text] [Related]
16. Diffuse distribution of tumor-infiltrating lymphocytes is a marker for better prognosis and chemotherapeutic effect in triple-negative breast cancer.
Hida AI; Watanabe T; Sagara Y; Kashiwaba M; Sagara Y; Aogi K; Ohi Y; Tanimoto A
Breast Cancer Res Treat; 2019 Nov; 178(2):283-294. PubMed ID: 31402409
[TBL] [Abstract][Full Text] [Related]
17. Relationship between the change in tumour-infiltrating lymphocyte level and residual tumour after neoadjuvant chemotherapy in patients with locally advanced breast cancer.
Erol VB; Goktas Aydin S; Bilici A; Cakir A; Acikgoz O; Olmez OF; Basim P
J Chemother; 2023 Nov; 35(7):662-670. PubMed ID: 37599454
[TBL] [Abstract][Full Text] [Related]
18. Negative Relationship between Post-Treatment Stromal Tumor-Infiltrating Lymphocyte (TIL) and Survival in Triple-Negative Breast Cancer Patients Treated with Dose-Dense Dose-Intense NeoAdjuvant Chemotherapy.
Giacchetti S; Faucheux L; Gardair C; Cuvier C; de Roquancourt A; Campedel L; Groheux D; de Bazelaire C; Lehmann-Che J; Miquel C; Cahen Doidy L; Amellou M; Madelaine I; Reyal F; Someil L; Hocini H; Hennequin C; Teixeira L; Espié M; Chevret S; Soumelis V; Hamy AS
Cancers (Basel); 2022 Mar; 14(5):. PubMed ID: 35267639
[TBL] [Abstract][Full Text] [Related]
19. Morphological Evaluation of Tumor-Infiltrating Lymphocytes (TILs) to Investigate Invasive Breast Cancer Immunogenicity, Reveal Lymphocytic Networks and Help Relapse Prediction: A Retrospective Study.
Romagnoli G; Wiedermann M; Hübner F; Wenners A; Mathiak M; Röcken C; Maass N; Klapper W; Alkatout I
Int J Mol Sci; 2017 Sep; 18(9):. PubMed ID: 28885584
[TBL] [Abstract][Full Text] [Related]
20. The Value of Tumor Infiltrating Lymphocytes (TIL) for Predicting the Response to Neoadjuvant Chemotherapy (NAC) in Breast Cancer according to the Molecular Subtypes.
Faur IF; Dobrescu A; Clim AI; Pasca P; Prodan-Barbulescu C; Gherle BD; Tarta C; Isaic A; Brebu D; Duta C; Totolici B; Lazar G
Biomedicines; 2023 Nov; 11(11):. PubMed ID: 38002037
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
